Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Want to cut your energy bills? Here’s how five experts are doing it 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced today its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS), Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.
Chief Executive Officer Mary Szela commented, “Today we join with others in the community to raise awareness of rare diseases. We are mindful of the challenges these patients, their families and caregivers face daily, and we are motivated by a passion to support advocacy and the development of treatments for these rare diseases.”
In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was established by EURORDIS and was first observed in Europe in 2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S. For more information about Rare Disease Day, visit www.rarediseaseday.us or www.rarediseaseday.org.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
